熱門資訊> 正文
AbCellera与PE公司合作开发抗体药物，创建公司
2024-05-01 23:44
- AbCellera (NASDAQ:ABCL) has inked an agreement with Viking Global Investors and ArrowMark Partners to develop new antibody drug programs, with an initial focus on immunology.
- The partnership also sees the formation of a new company, Newcos, for programs that are selected for advanced development.
- Terms call for the two private equity firms to head the initial process of program selection. That will be followed by a joint determination of the therapeutic product profile and then AbCellera (ABCL) beginning development of antibody drug programs.
- AbCellera will also advance programs to candidates and has an option to conduct cGMP manufacturing to support phase 1 clinical trials. Programs deemed successful will continue development though Newcos, with funding of that research coming from Viking and ArrowMark through company launch.
- The private equity firms will be the majority shareholders of Newcos, while AbCellera (ABCL) will be an equity founding partner with the potential for milestones payments and sales royalties.
- AbCellera has partnered with several prominent pharmas and biotechs, most recently with Biogen (BIIB).
More on AbCellera Biologics
- AbCellera: Victim Of Its Own Success
- AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript
- AbCellera Biologics: Continuing To Expand Partnerships
- Peter Thiel resigns from AbCellera board for personal reasons
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
